

THE INFLUENCE OF ANTICHOLINERGIC DRUG SELECTION ON THE EFFECTIVENESS OF OXIMES AGAINST SOMAN-INDUCED SUPRALETHAL POISONING IN MICE

Jiří Kassa

Purkyně Military Medical Academy, Hradec Králové: Department of Toxicology

Summary: 1. The influence of anticholinergic drugs (atropine, benactyzine, biperiden) on the efficacy of monopyrindinium and bispyridinium oximes (HI-6, BI-6, obidoxime, pralidoxime, methoxime) on soman-induced supralethal poisoning was studied in mice. 2. While methoxime combined with benactyzine or biperiden seems to be more efficacious in the elimination of toxic effects of supralethal dose of soman than its combination with atropine, the efficacy of the other oximes studied against soman-induced toxic effects is not significantly influenced by the anticholinergic drug selection. 3. On the other hand, there are big differences in the effectiveness of oximes tested as to their ability to eliminate toxic effects of soman at supralethal doses. 4. The findings support the fact that the choice of acetylcholinesterase reactivator is more important than the anticholinergic drug selection for the effectiveness of antidotal mixture in the case of prophylactic administration of antidotes.

Key words: Soman; Oximes; Anticholinergic drugs; Acute toxicity; Mice

Introduction

Despite the entry into force in April 1997 of the Chemical Weapons Convention forbidding the development, production, stockpiling and use of chemical warfare agents, the world has seen a rapid proliferation of such agents (17). The chemical warfare agents include different types of chemicals. The most important groups are nerve agents, highly toxic organophosphorus compounds (OPs) that exert their toxic effects by irreversible inhibiting the enzyme acetylcholinesterase (AChE, EC 3.1.1.7). Unfortunately, certain OPs are rather resistant to the standard antidotal treatment, which consists of anticholinergic drugs to counteract the accumulation of acetylcholine (ACh) and oximes to reactivate OP-inhibited AChE (4,14).

Soman (O-pinacolyl methylphosphonofluoridate) is an extremely toxic, centrally and peripherally acting nerve agent, which produces ACh accumulation leading to severe respiratory distress, prolonged limbic seizure, generalized convulsions and subsequent neuropathology in the brain (15). It appears to be one of the most resistant OPs to oxime reactivation because of rapid aging and the existence of a soman depot in the poisoned organisms (1,4,5,6).

While the ability of currently used monopyrindinium (pralidoxime) and bispyridinium oximes (obidoxime, methoxime) to eliminate toxic effects of soman is rather low, the H oximes seem to be relatively successful in antagonizing soman poisoning (9,11,12,19,20). Among the series of

H oximes, the HI-6 has been the most studied because it seems to be the most efficacious oxime, yet found, against toxic effects of soman (1,7,9,12,18). Recently, new asymmetric bispyridinium oxime, designated BI-6, has been synthesized at our Department of Toxicology to improve the efficacy of antidotal treatment of soman poisoning. It is an analogue of the oxime HI-6 that involves transbuten instead of propan linkage between pyridinium rings (3). Although the oxime BI-6 is also successful in antagonizing toxic effects of soman, it has no definite advantages over HI-6 in the antidotal treatment of acute soman poisoning (10).

Not only the choice of oximes but also the anticholinergic drug selection could influence the effectiveness of antidotes against OPs. The OP-induced poisoning is usually treated by an oxime in combination with the anticholinergic drug atropine. Nevertheless, there are other anticholinergic drugs that seem to be suitable adjuncts to oxime treatment of soman-induced poisoning (22). It has been described that some centrally acting cholinolytic drugs such as benactyzine are able to increase the ability of HI-6 to reactivate soman-inhibited AChE in comparison with atropine (8).

The present study compares the effects of currently used oximes (pralidoxime, obidoxime, methoxime) and H oximes (HI-6, BI-6) in combination with various anticholinergic drugs (atropine, benactyzin, biperiden) against supralethal dose of soman in mice in the case of prophylactic administration of antidotes.

Methods

Male mice weighing between 19 and 23 g were obtained from Konárovice. The animals were maintained in an air-conditioned room with light from 07.00 to 19.00 h and were allowed free access to standard food and tap water. The principles of laboratory animal care were followed and the handling of animals was made under the supervision of the Ethics Committee of Medical Faculty of Charles University and Purkyně Military Medical Academy in Hradec Králové.

Soman of 95 % purity was purchased from Zemianské Kostolany (Slovak Republic). Its purity was assayed by acidimetric titration. The oximes HI-6 and BI-6 of 98.5 % purity were synthesized at the Department of Toxicology of Purkyně Military Medical Academy in Hradec Králové. All other chemicals and drugs of analytical grade were obtained commercially and used without further purification.

The efficacy of oximes against soman administered intramuscularly (i.m.) at a supralethal dose (240 µg/kg, 2 x LD₅₀) was determined by the evaluation of their medium efficacy doses (ED₅₀ values) and their 95 % confidence limits using probit analysis of death occurring within 24 h following soman poisoning in at least four groups of six experimental animals (21). In these experiments, the oximes were injected i.m. in combination with one of the anticholinergic drugs used (atropine, benactyzine, biperiden) at equieffective doses (5 % LD₅₀) 5 min before challenge of soman. Finally, the safety of oximes administered at the efficacious doses was determined by the calculation of safety ratio (LD₅₀/ED₅₀ value, SR). The acute toxicity of all oximes tested in mice (LD₅₀ values) was also evaluated using probit - logarithmical analysis (21).

Statistical significance was determined by the use of Student's t-test and differences were considered significant when p < 0.05.

Results

The LD₅₀ values of all oximes tested are shown in Tab. 1. These values were used for the calculation of the safety of administration of oximes at efficacious doses.

The efficacy of each oxime in combination with various anticholinergic drugs is presented in Table 2. Pralidoxime as well as obidoxime appear to be ineffective against toxic effects of soman administered at supralethal dose regardless of the choice of anticholinergic drug in the case of the administration of pralidoxime and obidoxime at therapeutic doses (below 25 % LD₅₀). The effectiveness of H oximes (HI-6 and BI-6) does not change significantly when they are combined with various anticholinergic drugs. On the contrary, the prophylactic efficacy of methoxime depends on the selection of the anticholinergic drug. The combination of methoxime with benactyzine or biperiden is significantly more efficacious in antagonizing toxic effect of soman than the combination of methoxime with atropine (p < 0.05).

To compare the efficacious doses of oximes studied, capable of elimination of toxic effects of soman at a supralethal dose, H oximes seem to be significantly more efficacious in antagonizing lethal effects of soman than other oximes tested regardless of the choice of anticholinergic drugs (p < 0.05) (Tab. 2).

Tab. 1: LD₅₀ values of oximes following i.m. administration in mice

OXIME	LD ₅₀ (mg/kg) ± 95 % confidence limit
Pralidoxime	263.6 (253.7 - 273.8)
Obidoxime	188.4 (156.3 - 208.0)
Methoxime	641.8 (590.5 - 716.0)
HI-6	671.3 (627.4 - 718.3)
BI-6	266.3 (248.5 - 285.4)

Tab. 2: The prophylactic antidotal potency (ED₅₀ value) and safety ratio (SR) of oximes in combination with various anticholinergic drugs in soman-poisoned mice. Statistical significance: * p < 0.05.

OXIME	Cholinolytic drug	ED ₅₀ (mg/kg) ± 95 % confidence limits	SR (LD ₅₀ /ED ₅₀)
PRALI-DOXIME	Atropine	> 70	< 4.0
	Benactyzine	> 70	< 4.0
	Biperiden	> 70	< 4.0
OBI-DOXIME	Atropine	> 50	< 4.0
	Benactyzine	> 50	< 4.0
	Biperiden	> 50	< 4.0
METHOXIME	Atropine	105.7 (95.5 - 117.1)	6.1
	Benactyzine	50.5 (33.9 - 73.0)*	12.7
	Biperiden	25.8 (19.6 - 34.9)*	26.0
HI-6	Atropine	7.2 (6.1 - 8.4)	93.2
	Benactyzine	7.0 (4.2 - 11.2)	95.6
	Biperiden	5.9 (3.7 - 9.5)	113.0
BI-6	Atropine	11.7 (10.1 - 13.5)	22.8
	Benactyzine	10.4 (8.3 - 12.8)	18.8
	Biperiden	5.6 (2.8 - 11.5)	47.4

Discussion

Nerve agents are still considered to be the most important chemical warfare agents. With the existing threat of the use of chemical weapons not only in military conflicts but also in terroristic attacks, the search for effective protection is in the central concern of different laboratories both civilian and military (4,16).

The effectiveness of oximes against the toxic effects of nerve agents including soman is usually tested in combination with atropine (13, 20). Nevertheless, some other anticholinergic drugs (e.g. benactyzine, biperiden) should be more advantageous than atropine for the elimination of toxic effects of nerve agents because of their central antimuscarinic effects (2,22). However, our results do not confirm an influence of anticholinergic drug selection on the effi-

cacy of oximes in antagonizing the toxic effects of soman at the supralethal dose in the case of the prophylactic administration of antidotes. With the exception of methoxime, the therapeutical effects of oximes was not significantly influenced by the change of anticholinergic drug in antagonizing soman-induced poisoning in mice. The H oximes, especially HI-6, were the most efficacious in eliminating soman-induced toxicity regardless of the choice of anticholinergic drug (9,11).

Although benactyzine as well as biperiden seem to be able to increase the ability of methoxime to eliminate soman-induced toxicity in comparison with atropine, methoxime does not reach the effectiveness of H oximes against soman regardless of the selection of anticholinergic drug (11).

In conclusion, our data indicate that the choice of AChE reactivators is more important for the survival of soman-poisoned experimental animals than the selection of anticholinergic drugs in the case of prophylactic administration of antidotes.

Acknowledgement

The author thanks to Mrs J. Petrová for her technical assistance and help with statistical evaluation.

References

1. Bajgar J. Present view on toxodynamics of soman poisoning. *Acta Med (Hradec Králové)* 1996;39:101-5.
2. Bajgar J, Fusek J, Vachek J. Treatment and prophylaxis against nerve agent poisoning. *ASA Newslett* 1994;94-4:10-1.
3. Bielařský J, Kassa J, Elsnerová I, Dejmenk L. Cholinesterase reactivators derived from pyridine-2-carbaldoxime. *Coll Czech Chem Commun* 1998;63:199-204.
4. Dawson RM. Review of oximes available for the treatment of nerve agent poisoning. *J Appl Toxicol* 1994;14:317-31.
5. Fleisher JH, Harris LW. Dealkylation as a mechanism for aging of cholinesterase after poisoning with pinacolyl methylphosphonofluoridate. *Biochem Pharmacol* 1965;14:641-9.
6. Kadar T, Raveh L, Cohen G, Oz N, Baraness I, Balon A, Ashani Z, Shapira S. Distribution of ³H-soman in mice. *Arch Toxicol* 1985;58:45-9.
7. Kassa J. Comparison of efficacy of two oximes (HI-6 and obidoxime) in soman poisoning in rats. *Toxicology* 1995;101:167-74.
8. Kassa J. Importance of cholinolytic drug selection for the efficacy of HI-6 against soman in rats. *Toxicology* 1997;116:147-52.
9. Kassa J, Cabal J, Bajgar J, Szinicz L. The choice: HI-6, pralidoxime or obidoxime against nerve agents? *ASA Newslett* 1997;97-4:16-8.
10. Kassa J. A comparison of the efficacy of new asymmetric bispyridinium oxime BI-6 with other oximes (obidoxime, HI-6) against soman in rats. *Hum Exp Toxicol* 1998;17:331-5.
11. Kassa J, Cabal J. A comparison of the efficacy of a new asymmetric bispyridinium oxime BI-6 with currently available oximes and H oximes against soman by in vitro and in vivo methods. *Toxicology* 1999;132:111-8.
12. Koplovitz I, Stewart JR. A comparison of the efficacy of HI-6 and 2-PAM against soman, tabun, sarin and VX in the rabbit. *Toxicol Lett* 1994;70:169-79.
13. Koplovitz I, Menton R, Matthew C, Shutz M, Nalls C, Kelly S. Dose-response effects of atropine and HI-6 treatment of organophosphorus poisoning in guinea-pigs. *Drug Chem Toxicol* 1995;18:119-31.
14. Marrs TC. Organophosphate poisoning. *Pharmacol Ther* 1993;58:51-66.
15. McDonough JH Jr, Shih T-M. Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. *Neurosci Biobehav Rev* 1997;21: 559-79.
16. Ohtomi S, Takase M, Kumagai F. Sarin poisoning in Japan. A clinical experience in Japan Self Defense Force (JSDF) Central Hospital. *Int Rev Arm Ser* 1996;69:97-102.
17. Polhuijs M, Langenberg JP, Benschop H. New method for retrospective detection of exposure to organophosphorus anticholinesterases: application to alleged sarin victims of Japanese terrorists. *Toxicol Appl Pharmacol* 1997;146:156-61.
18. Rousseaux CG, Dua AK. Pharmacology of HI-6, an H series oximes. *Can J Physiol Pharmacol* 1989;67:1183-9.
19. Shih T-M, Whalley ChE, Valdes JJ. A comparison of cholinergic effects of HI-6 and pralidoxime-2-chloride (2-PAM) in soman poisoning. *Toxicol Lett* 1991;55:131-47.
20. Shih T-M. Comparison of several oximes on reactivation of soman-inhibited blood, brain and tissue cholinesterase activity in rats. *Arch Toxicol* 1993;67:637-46.
21. Tallarida R, Murray R. *Manual of pharmacological calculation with computer programs*. New York: Springer-Verlag, 1987:p.145.
22. Vachek J, Kassa J, Fusek J, Bajgar J. New possibilities of treatment of poisoning with organophosphorus compounds. *Sbor věd Práci VLA JEP (Hradec Králové)* 1993;116:67-95.

Submitted December 2000.

Accepted July 2001.

**Doc. MUDr. Jiří Kassa, CSc.,
Purkyně Military Medical Academy,
P.O. Box 35/T,
500 01 Hradec Králové,
Czech Republic.
e-mail: kassa@pmfhk.cz**